Geraud, A. et al. Clinical pharmacology and interplay of immune checkpoint agents: a yin–yang balance. Annu. Rev. Pharmacol. Toxicol. 61, 85–112 (2021).
Banchereau, R. et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat. Commun. 12, 3969 (2021).
Wang, X. et al. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann. Oncol. 35, 508–522 (2024).
Fendler, A. et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat. Rev. Clin. Oncol. 19, 385–401 (2022).
Johnson, D. B. et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat. Med. 25, 1243–1250 (2019).
Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410–416 (2021).
Verbeke, R., Hogan, M. J., Lore, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993–2005 (2022).
Grippin, A. J. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647, 488–497 (2025).
Chemaitelly, H. et al. Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar. eLife 14, e103690 (2025).
Jee, J. et al. Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival in a Pandemic (Cold Spring Harbor Laboratory, 2025).
Ruiz, J. I., Lopez-Olivo, M. A., Geng, Y. & Suarez-Almazor, M. E. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. J. Immunother. Cancer 11, e006246 (2023).
Waissengrin, B., Agbarya, A., Safadi, E., Padova, H. & Wolf, I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 22, 581–583 (2021).
Mei, Q. et al. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study. J. Immunother. Cancer 10, e004157 (2022).
Maillard, O. et al. Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase. Therapie 79, 659–669 (2024).
Salem, J. E. et al. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Eur. Heart J. 47, 1014–1030 (2025).
Jourdain, H. et al. PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study. Lancet Reg. Health Eur. 59, 101484 (2025).
Hernan, M. A. How to estimate the effect of treatment duration on survival outcomes using observational data. BMJ 360, k182 (2018).
Semenzato, L. et al. COVID-19 mRNA vaccination and 4-year all-cause mortality among adults aged 18 to 59 years in France. JAMA Netw. Open 8, e2546822 (2025).
Parikh, R. B. et al. Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers. JAMA Oncol. 7, 1843 (2021).
Meyers, D. E. et al. Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors. JTO Clin. Res. Rep. 4, 100482 (2023).
Kapoor, A. et al. Immune checkpoint inhibitors in patients with solid tumors and poor performance status. Medicine 100, e25115 (2021).
Hernan, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758–764 (2016).
Hernan, M. A., Sauer, B. C., Hernandez-Diaz, S., Platt, R. & Shrier, I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J. Clin. Epidemiol. 79, 70–75 (2016).
Maringe, C. et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int. J. Epidemiol. 49, 1719–1729 (2020).
Constantinou, P., Jean, C., Canoui-Poitrine, F. & Ferrat, E. Non-COVID-19 mortality among older people or with chronic conditions during year 2020 in France: a nationwide cohort study. BMC Public Health 25, (2025).
Rey, G., Bounebache, K. & Rondet, C. Causes of deaths data, linkages and big data perspectives. J. Forensic Leg. Med. 57, 37–40 (2018).
Collaborators, G. B. D. C. The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1565–1586 (2025).
Rey, G., Jougla, E., Fouillet, A. & Hemon, D. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 9, 33 (2009).
Rousseau, A. et al. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg. Health Eur. 43, 100970 (2024).
Austin, P. C., Lee, D. S. & Fine, J. P. Introduction to the analysis of survival data in the presence of competing risks. Circulation 133, 601–609 (2016).
